Welchol Logo - Two goals, one therapy

Efficacy of Welchol in Primary Hyperlipidemia

Sign Up for Updates

Be notified about site updates, educational opportunities, and more.

Significant LDL-C Reductions

In patients with primary hyperlipidemia, make Welchol the preferred partner to a statin for significant LDL-C reductions in your patients. Welchol increased efficacy without increasing the statin dose.

On this page:

Welchol + simvastatin


Welchol added to simvastatin can help your patients achieve significant LDL-C and HDL-C improvements*1,2

Welchol (colesevelam HCl)

In this clinical trial, the most common adverse reactions observed by ≥5% of the subjects after receiving Welchol were flatulence and constipation.

Knapp HH, et al. Am J Med. 2001

Please see Study Design B

Welchol + atorvastatin


Comparable LDL-C reductions between atorvastatin 80 mg and atorvastatin 10 mg + Welchol 3.8g*,1,3

Welchol (colesevelam HCl)

In this clinical trial, the most common adverse reactions observed by ≥5% of the subjects after receiving Welchol were flatulence and constipation.

Hunninghake D, et al. Atherosclerosis. 2001

Please see Study Design C

Welchol: an alternative to statin titration


Adding Welchol can give your patients an alternative to statin titration1,4

Welchol (colesevelam HCl)

Add Welchol to statin therapy to help more of your patients achieve their LDL-C goals

Study Designs

Study Design B (Knapp HH, Am J Med. 2001)

Results from a 6-week, multicenter, randomized, double-blind, placebo-controlled study of 258 randomized patients with moderate hypercholesterolemia* (LDL-C ≥160 mg/dL;
TG ≤300 mg/dL) who were not on lipid-lowering medication. Patients were randomized to 1 of the following treatment regimens: placebo, Welchol 3.8 g/day, simvastatin 10 mg/day, Welchol 3.8 g/day + simvastatin 10 mg/day, Welchol 2.3 g/day, simvastatin 20 mg/day, or Welchol 2.3 g/day + simvastatin 20 mg/day.1,2

Study Design C (Hunninghake D, Atherosclerosis. 2001)

Results from a randomized, double-blind, placebo-controlled, 4-week study of 94 randomized patients with moderate hypercholesterolemia* (LDL-C ≥160 mg/dL, TG ≤300 mg/dL) and
LDL-C levels ranging from 156-236 mg/dL. Patients were assigned to 1 of 5 treatment groups: placebo, Welchol 3.8 g/day, atorvastatin 10 mg/day, atorvastatin 80 mg/day, or atorvastatin 10 mg/day + Welchol 3.8 g/day.1,3

*Hypercholesterolemia is now referred to as primary hyperlipidemia

Welchol On Demand

Access recent Webcasts from leading physicians

Important Safety Information
Important Safety Information

References

1. Welchol (colesevelam HCl). Prescribing Information. Daiichi Sankyo, Inc., Parsippany, NJ, 2009.

2. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001;110(5):352-360.

3. Hunninghake D, Insull W Jr, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158:407-416.

4. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid altering drug. Expert Opin Pharmacother. 2003;4(5):779-790.

This information is intended for U.S. healthcare professionals only.
© 2010 Daiichi Sankyo, Inc.